• 🌎 Worldwide
    • 🇺🇸 U.S.
    • 🇨🇦 Canada
    • 🇬🇧 United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Health

Drug Trial Planned For Synthetic Cannabinoid COVID-19 Treatment

By using this powerful anti-inflammatory, a Philadelphia cannabis company believes it can mitigate the immune response triggered by COVID-19.

Brendan Bures by Brendan Bures
June 8, 2020
in Health, Investments, Marijuana Stocks
Cannabis Clinical Trials

Photo Credit - manjurulhaque via Twenty20

177
SHARES
ShareShare

A Philadelphia cannabis firm has joined the race to create a COVID-19 cure using cannabinoids. FSD Pharma announced last week that the Food and Drug Administration (FDA) had approved the company’s application proposal to conduct clinical trials around the medicine. The treatment will use a drug called ultramicronized palmitoylethanolamid (or micro PEA) that includes synthetic molecules that mimic cannabinoids.

Micro PEA is a unique drug. It’s believed to act as an anti-inflammatory and promoted between 1969 and 1979 in former Czechoslovakia as treatment for influenza and the common cold. Clinical trials conducted at the time showed PEA was an effective prophylactic in respiratory infection, with no registered side effects. According to scientists behind the research, it could act as a quick therapeutic answer should a flu epidemic occur.

Today, the drug is promoted as a prescription nutraceutical in Italy and used to treat chronic inflammation. Pharmaceutical firm Epitech Group owned the rights to the drug and sold it under the names Normast and Pelvilen. Earlier this year, FSD, which is headquartered in Toronto, Canada, purchased the worldwide rights from Epitech for $17.5 million and re-branded it as FSD-201.

“We contacted the FDA in late-March 2020 after becoming aware that several Italian physicians and scientists were advocating for use of ultramicronized PEA for patients suffering from symptoms of COVID-19, based on the drug’s mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines,” Philadelphia-based physician and FSD CEO Raza Bokhari said in a statement.

In an interview with The Philadelphia Inquirer, Bokhari emphasized that FSD does not claim cannabinoids, synthetic or plant-based, is an alternative for COVID-19 treatment. But the CEO said FSD-201 modulates the endocannabinoid system as “a naturally occurring fatty acid” by targeting CB2 receptors, which are believed to affect pain and inflammation in humans.

“Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm,” Bokhari told the Inquirer. “[FSD-201] is not a virus killer. But we believe it can mitigate that immune response, which can be fatal.”

Previous research published in Preprints suggested marijuana could manipulate the main cellular gateway that COVID-19 enters the system. Researchers wrote that a novel combination of cannabinoids “may become a useful addition to the treatment of COVID-19.” Israeli researchers have also launched clinical trials into whether marijuana terpenes could affect and/or prevent COVID-19.

The Fresh Toast

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: biotechCOVID-19CSE:HUGEFSD Pharma Inc.NASDAQ:HUGEOTC:FSDDF

Get Real-Time Updates from MJobserver.com

Unsubscribe
Brendan Bures

Brendan Bures

Brendan Bures is the Culture Editor at The Fresh Toast covering everything from celebrities to cannabis.

Related Posts

Cannabis Investor Conference News
Briefs

Skye Bioscience to Present at Upcoming Investment Conferences in April

April 15, 2021
Epidiolex from GW Pharmaceuticals
Investments

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021
Epidiolex from GW Pharmaceuticals
Investments

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

October 21, 2020
Epidiolex from GW Pharmaceuticals
Executives

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

September 10, 2020
Marinol Dronabinol THC Pharmaceutical
Events

30+ Expert Speakers to Present at the 3rd Annual Cannabinoid-Derived Pharmaceuticals Summit

July 9, 2020
Health Canada Licensed Cannabis Producer and Processor Stocks
Press Releases

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

June 18, 2020
Load More
Next Post
Cannabis Stock Market News

5 of Today’s Biggest Marijuana Stock Gainers on Monday, June 8th, 2020

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

✉️ Subscribe to Our Newsletter!

* indicates required

🔎 Search Marijuana Stocks

📰 Recent News

  • J. Arnold Wealth Management Discloses New Stake in Cannabis ETF
  • Bank of America Increases its SNDL Holdings
  • The Lift & Co. Expo is back helping Canada build responsible, prosperous cannabis and psychedelics businesses
  • Bank of America Trims its Stake in Canopy Growth Corp.
  • Ballard Spahr Launches Cannabis Legislation Tracker to ID Industry Trends and Opportunities
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • 🇺🇸 United States
  • 🇨🇦 Canada
  • 🇬🇧 United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • 📅 Calendar
  • 📊 Databases
  • 📇 Directories
  • 🔔 RSS Feeds
  • 📺 Videos

Find Cannabis Business Services

  • ⚖️ Attorneys & Law Firms
  • 📊 Accountants & Accounting Firms
  • 💡 Consultants & Consulting Firms
  • 📲 Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • 👀 Advertise
  • 📣 DMO Newswire
  • 📇 List in Our Databases

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.